Evidence map›Paper›PMID 29541386›Full record

ArticleOncotarget2018

ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines.

Maeva Dufies, Damien Ambrosetti, Sonia Boulakirba, Anne Calleja, Coline Savy, Nathan Furstoss, Marwa Zerhouni, Julien Parola, Lazaro Aira-Diaz, Sandrine Marchetti and 7 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Maeva DufiesUniversité Côte d'Azur, C3M/Inserm U1065, Nice, France.
Damien AmbrosettiUniversité Côte d'Azur, CHU Nice, Department of Pathology, Nice, France.
Sonia BoulakirbaUniversité Côte d'Azur, C3M/Inserm U1065, Nice, France.
Anne CallejaUniversité Côte d'Azur, C3M/Inserm U1065, Nice, France.
Coline SavyUniversité Côte d'Azur, C3M/Inserm U1065, Nice, France.
Nathan FurstossUniversité Côte d'Azur, C3M/Inserm U1065, Nice, France.
Marwa ZerhouniUniversité Côte d'Azur, C3M/Inserm U1065, Nice, France.
Julien ParolaUniversité Côte d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR 7284, INSERM U 1081, Nice, France.
Lazaro Aira-DiazUniversité Côte d'Azur, C3M/Inserm U1065, Nice, France.
Sandrine MarchettiUniversité Côte d'Azur, C3M/Inserm U1065, Nice, France.
Francois OrangeUniversité Côte d'Azur, CCMA, Nice, France.
Sandra Lacas-GervaisUniversité Côte d'Azur, CCMA, Nice, France.
Frederic LucianoUniversité Côte d'Azur, C3M/Inserm U1065, Nice, France.
Arnaud JacquelUniversité Côte d'Azur, C3M/Inserm U1065, Nice, France.
Guillaume RobertUniversité Côte d'Azur, C3M/Inserm U1065, Nice, France.
Gilles PagèsUniversité Côte d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR 7284, INSERM U 1081, Nice, France.
Patrick AubergerUniversité Côte d'Azur, C3M/Inserm U1065, Nice, France.
Université Côte d'Azur · FRInserm · FRFondation de France · FRInstitut de Recherche sur le Cancer et le Vieillissement de Nice · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polo-like kinases (Plks) define a highly conserved family of Ser/Thr kinases with crucial roles in the regulation of cell division. Here we show that Plk1 is cleaved by caspase 3, but not by other caspases in different hematopoietic cell lines treated with competitive inhibitors of the ATP-binding pocket of Plk1. Intriguingly, Plk1 was not cleaved in cells treated with Rigosertib, a non-competitive inhibitor of Plk1, suggesting that binding of the inhibitor to the ATP binding pocket of Plk1 triggers a conformational change and unmasks a cryptic caspase 3 cleavage site on the protein. Cleavage occurs after Asp-404 in a DYSD/K sequence and separates the kinase domain from the two PBDs of Plk1. All Plk1 inhibitors triggered G2/M arrest, activation of caspases 2 and 3, polyploidy, multiple nuclei and mitotic catastrophe, albeit at higher concentrations in the case of Rigosertib. Upon BI-2536 treatment, Plk1 cleavage occurred only in the cytosolic fraction and cleaved Plk1 accumulated in this subcellular compartment. Importantly, the cleaved N-Terminal fragment of Plk1 exhibited a higher enzymatic activity than its non-cleaved counterpart and accumulated into the cytoplasm conversely to the full length and the C-Terminal Plk1 fragments that were found essentially into the nucleus. Finally, the DYSD/K cleavage site was highly conserved during evolution from

Indexed as

caspasesG2M arresthematopoietic cellsmitotic catastrophePlk1

Identifiers

PMID29541386
PMCPMC5834281
OpenAlexW2779905914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.